NASDAQ: RXRX · Biotechnology
Over the past week, Recursion Pharmaceuticals (RXRX) saw about 24 mentions across Reddit, X and news, and the read is an Adanos Buy. The crowd averages 64% bullish but is far apart: News runs 100% bullish while X sits at just 31%. Wall Street is more cautious, with 3 of 7 analysts rating RXRX a buy.
There is little buzz around RXRX this week and little agreement on direction, which is why it reads as a Buy.
Wall Street’s 43% buy share sits next to a crowd that ranges from X at 31% to News at 100%. No other tracker puts the two side by side.
Across 7 analysts the consensus is a Hold: 3 buy calls against 0 sell, with an average 12-month price target of $7.22.
The Adanos signal blends each source’s bullish ratio, source breadth, buzz intensity and 3-day momentum. This week bullish sits above the neutral line, momentum is cooling and the 3 sources disagree sharply, so the read is a Buy.
The crowd runs 21 points hotter than the 43% analyst buy share, retail is ahead of the Street here. The split is inside the crowd: News reads 100% bullish while X sits at 31%, a 69-point spread that single-source trackers miss.
Weekly price context: this Alpha Vantage chart keeps its own dated range; the sentiment metrics elsewhere on this page may be newer. Over the 30-day window, Recursion Pharmaceuticals (RXRX) buzz held subdued around 31.4 while the price drifted up 14.2% across the period. The chart tracks how social and news attention moved against end-of-day price. Average daily trading volume across the displayed trading days is 15.2M shares. Over the last 7 trading days, RXRX gained 5.5%. Buzz activity in the recent week averaged 28.8 and was relatively stable, swinging between 20.9 and 34.1. Recent volume is in line with the 30-day average, reflecting steady institutional and retail participation. Daily crowd sentiment leaned bullish on 17 of the 21 days with directional mentions, shown as the green, grey and red breakdown bars below the chart.
Signal metrics use the latest 7 days; contributor and breadth context uses the 30-day chart window.
No Polymarket data for this stock this week.
Query sentiment for RXRX and 2001+ stocks from your terminal. Filter by source, timeframe and signal strength.
View CLIEmbed live RXRX sentiment on your own site with drop-in web components.
View WidgetsThis week’s sentiment from Adanos, with fundamentals and analyst consensus. A quick-reference snapshot for Sep 06, 2026.
| Adanos signal | Buy |
|---|---|
| Analyst consensus | Hold (3 / 4 / 0) |
| Crowd bullish (7d) | 64% |
| Avg price target | $7.22 |
| Most bullish source | News, 100% |
| Most bearish source | X, 31% |
| Sentiment spread | 69 pts |
| Mentions (7d) | 24 |
| Market cap | $1.84B |
| EPS · Beta | -$1.02 · 1.1 |
| Revenue (TTM) | $54.9M · 0% margin |
| Industry | Biotechnology |
Based on aggregated sentiment from Reddit, X and News sources, Recursion Pharmaceuticals (RXRX) currently carries an Adanos buy signal with 92/100 conviction. The current cross-source average reads 64% bullish across 3 active sources. Those sources contribute 24 tracked mentions over the last 7 days. This is a sentiment-based reading, not financial advice.
Reddit discussion around Recursion Pharmaceuticals (RXRX) is fairly quiet with 8 mentions over the last 7 days; the 30-day context spans 13 tracked subreddits. The 7-day tone is 62% bullish; 3-day activity momentum is falling, suggesting cooling attention.
The crowd reads bullish on Recursion Pharmaceuticals (RXRX), averaging 64% bullish across 3 tracked sources over the last 7 days. The two ends of the range are News at 100% bullish and X at 31%, a 69-point spread. On the professional side, 3 of 7 analysts rate RXRX a buy.
Of the 7 analysts covering Recursion Pharmaceuticals (RXRX), 3 rate it a buy, 4 a hold and 0 a sell, for a hold consensus. The average price target is $7.22. The crowd is the more bullish of the two, averaging 64%.
Recursion Pharmaceuticals (RXRX)'s cross-source average is bullish at 64% bullish. Source readings are split: 2 sources lean bullish and 1 source leans bearish. Reddit reads 62% bullish, News reads 100% bullish and x coverage is the most negative at 31% bullish. The combined signal points to broad buy-side pressure with 92/100 conviction.
The cross-source average is bullish for Recursion Pharmaceuticals (RXRX) at 64% bullish. Source readings are split: 2 sources lean bullish and 1 source leans bearish. The most bearish reading is x at 31% bullish. 3-day activity momentum is falling across Reddit and X. The buy signal carries 92/100 conviction.
X is the dominant discussion channel with 13 mentions (54% of total volume). Reddit contributes 8 mentions and News contributes 3 mentions. The cross-source average is bullish at 64% bullish. Source readings are split: 2 sources lean bullish and 1 source leans bearish.
The Adanos signal blends bullish ratio, buzz score, source breadth and 3-day activity momentum into a single buy/sell reading. RXRX's buy signal at 92/100 conviction reflects a bullish cross-source average at 64% bullish. Source readings are split: 2 sources lean bullish and 1 source leans bearish. It is a research shortcut, not financial advice.
The RXRX sentiment page is regenerated from the latest 7-day tracking window at each build. Data reflects the most recent Reddit posts, tweets and news articles available in the current publishing cycle.
Peers are ranked first by matching the Buy signal, then by the closest bullish ratio. Discussion activity breaks any remaining ties.
Every data point on this page comes from the Adanos sentiment APIs. Get a free API key and start querying Reddit, X, News and Polymarket sentiment programmatically.
Get Free API Key